Health-care companies rose amid ongoing enthusiasm about obesity drugs. Shares of Danish drugmaker Novo Nordisk rose by more than 3% as traders bet demand.
Hundreds of online sellers are offering Eli Lilly’ & Co.’s retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory.